publication date: Apr. 1, 2016
At a meeting of the NCI Board of Scientific Advisors March 29, NCI officials had good news to report:
• The appropriations are increasing, with bipartisan support to boot.
• The White House “moonshot” initiative on cancer is bringing new money and new urgency to the institute’s work.
The cancer program has seen many aggressive mandates and has made many big promises, and it’s worthwhile to remember this current initiative is being launched by an administration that is concluding its term.
AVEO Execs Face Fraud Charges from SEC;
Company to Pay $4 Million to Settle
The Securities and Exchange Commission March 29 announced fraud charges against AVEO Pharmaceuticals Inc., a biotechnology company, and three of its former executives.
SEC said the company agreed to pay a $4 million penalty to settle the charges without admitting or denying the allegations.
The agency said it is continuing to pursue its case against three of AVEO’s former officers: CEO Tuan Ha-Ngoc, Chief Financial Officer David Johnston, and Chief Medical Officer William Slichenmyer.
Schools of Public Health: Cancer Moonshot Undervalues Prevention
Over 70 deans and directors of public health programs and institutes signed a letter March 21 asking the White House for to prioritize federal investments in public health and cancer prevention.
The letter, addressed to Vice President Joe Biden, urges the administration to “pay careful attention to the balance between treatment and prevention-related investments.”
Dinah Singer and Warren Kibbe named acting NCI deputy directors
Peter Paul Yu named physician-in-chief at Hartford HealthCare Cancer Institute
Greg Simon named executive director of national cancer moonshot initiative
- Johns Hopkins launches Bloomberg-Kimmel Institute for Cancer Immunotherapy
Hyundai Hope on Wheels announces $1 million in pediatric research grants
MD Anderson and TESARO form immuno-oncology collaboration
|Drugs and Targets|